Journeying with you on a psychedelics business trip of a lifetime
Canada has made a name for itself in the world of plant medicine. Having led the charge with cannabis, the Canadian market has recently turned its attention to the power of psychedelics. MDMA, ecstasy, ketamine, psilocybin and others are poised to change the landscape of the pharmaceutical industry, with groundbreaking new research proving the impressive efficacy of these compounds in treating a variety of issues; most notably, Major Depressive Disorder, PTSD and chronic pain.
As Canada’s regulations evolve, the business landscape will change to accommodate new regulatory adjustments. As early supporters of the psychedelics industry and seasoned cannabis business experts, the team at Zeifmans is equipped to help your business navigate the path to success in this exciting industry.
Zeifmans supports psychedelics companies by:
Identifying new opportunities as regulations shift to further embrace the industry.
Establishing financial systems that enable compliance in accordance with the future of the industry.
Preparing for future growth by executing cost-effective audits of financial statements, and advising on financing options through IPO’s, mergers, and acquisitions.
Establishing a corporate structure that’s growth-oriented and sustainable.
Our industry experts work with you 1:1 to develop tailor-made strategies that achieve your goals for future expansion. Our team has contacts within the Canadian psychedelics market and extending into the global market via our Nexia International network.
To learn more about how Zeifmans can assist your psychedelics business in achieving your goals throughout every phase of the business life cycle, send us an email today.
Listen to our podcast series, Micro-dosing with Zeifmans: Short podcasts on demystifying the business of psychedelics.